Biodesix Inc (BDSX) · Nov 5, 2026 · Earnings

Biodesix Q3 earnings miss as 2026 guidance falls sharply

Miss — Revenue $24.0M vs ~$27.5M consensus

Biodesix’s Q3 earnings show healthy diagnostic test growth, but a major revenue miss and sharp 2026 guidance cut expose execution delays.

Biodesix is scaling blood-based lung diagnostics while expanding into digital diagnostics and molecular residual disease monitoring; the immediate challenge is converting that product and clinical momentum into repeatable commercial growth. Before this filing, the company had maintained a 2026 revenue outlook of $108M-$114M, while published Q3 revenue consensus was approximately $27.5M.

The quarter materially missed the revenue bar. Revenue reached $24.0M, up 10% year over year, but was roughly 12.5% below consensus; the shortfall was concentrated in weaker-than-expected execution rather than a collapse in diagnostic demand.

MetricQ3 2026Q3 2025Consensus / prior guide
Total revenue (Financial Highlights)$24.0M (-12.5%)$21.8M~$27.5M consensus
Diagnostic Testing revenue (Financial Highlights)$23.0M (+16%)$19.8M
Test volume (Financial Highlights)19,400 (+24%)15,600
Gross margin (Financial Highlights)81%81%
Net loss (Statements of Operations)$(8.0)M (+8%)$(8.7)M
Adjusted EBITDA loss (Reconciliation)$(3.9)M (+16%)$(4.6)M
FY2026 revenue guidance (2026 Financial Outlook)$101M-$103M$108M-$114M prior

Core diagnostic demand held up, but monetization and execution weakened. Diagnostic Testing revenue grew 16% and volumes grew 24%, yet lower average revenue per test diluted the benefit, while Development Services revenue fell to $1.0M from $1.9M because projects started and were recognized later than expected.

The guidance cut is the clearest change to the business story. Management reduced the full-year revenue range by $7M-$11M, acknowledging fewer productive sales representatives, heavier seasonality, and delayed customer-dependent projects. The roughly 15% midpoint growth target now implies a substantially slower year than the previously expected 25% midpoint growth.

Loss improvement does not offset the top-line reset. Gross margin stayed high at 81%, and both net loss and Adjusted EBITDA loss improved year over year, but the company remains loss-making and used $6.3M of at-the-market proceeds during the quarter even as cash declined from the prior quarter.

Bottom line: Biodesix still has real volume growth and improving operating losses, but this filing resets the near-term growth story lower. The issue is execution and timing today; the magnitude of the guidance cut makes it a clearly negative earnings event rather than a routine slowdown.

What to watch next

Q4 results, expected early 2027

Original filing on SEC EDGAR

More Biodesix Inc news

Biodesix Q3 earnings miss as 2026 guidance falls sharply | BDSX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.